{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:17:17Z","timestamp":1772583437733,"version":"3.50.1"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["por-journal.com"],"crossmark-restriction":true},"short-container-title":["Pathol. Oncol. Res."],"abstract":"<jats:p>Pazopanib is a tyrosine-kinase inhibitor also used for the treatment of advanced soft tissue sarcomas. Our retrospective study analyzed real-world data of stage 4 sarcoma patients treated with pazopanib in our department in the past 10\u00a0years. Data were collected from the Medworks medical system, which is used for daily work in our center. A total of 99 patients were included: 46 men and 53 women The median age at the diagnosis was 49.8\u00a0years. The most common histological subtypes were leiomyosarcoma and synovial sarcoma. All patients received 800\u00a0mg of pazopanib per day, which was reduced to 400\u00a0mg in the event of toxicity. Treatment was continued until disease progression or unmanageable toxicity. The primary endpoint of the study was progression-free survival and the secondary endpoints were overall survival, overall response rate and disease control rate. The results in relation to demographic data, previous treatments, localizations of primary tumors and metastasis and histological subtypes were analyzed. In our center pazopanib was most frequently used in the third line. In total, 61 patients received perioperative therapy; the most common regimen used in the metastatic setting was VIP. Median PFS and OS were 3\u00a0months and 7\u00a0months, respectively. ORR was 14% and DCR was 40.45%. Dose reductions were necessary during the treatment of 56 patients. Hematological toxicity was detected in 23% of cases, with the most frequent events being grade 1 thrombocytopenia and grade 2 leukocytopenia. Non-hematological adverse events were documented in half of the patients. Pazopanib was more effective in earlier lines of treatment. Compared to the PALETTE phase 3 trial more patients received perioperative therapy, median PFS and OS were shorter (3\u00a0months vs. 4.6\u00a0months and 7\u00a0months vs. 11.9\u00a0months) and ORR was higher (14% vs. 9%) in our patient population. Dose reductions were more frequent in our center. Pazopanib is a therapeutic option for the treatment of advanced soft tissue sarcoma, also according to real-world data. Further investigations are needed to select patients who can benefit the most from pazopanib and to determine the most appropriate sequence of therapy.<\/jats:p>","DOI":"10.3389\/pore.2025.1611965","type":"journal-article","created":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T05:02:06Z","timestamp":1743483726000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world experience with pazopanib in locally advanced and metastatic soft tissue sarcomas: a Hungarian retrospective single-center study"],"prefix":"10.3389","volume":"31","author":[{"given":"N\u00f3ra","family":"Ecker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marietta","family":"Aranyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edina","family":"Kiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N\u00f3ra","family":"Kiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"Lahm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zs\u00f3fia","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e1rta","family":"Sikter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1d\u00e1m","family":"Szab\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anik\u00f3 Sz\u00e1szn\u00e9","family":"Szentesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kl\u00e1ra","family":"Tak\u00e1cs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Uhlyarik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f3zsef","family":"Vachaja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Seb\u0151k","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zsuzsanna","family":"P\u00e1pai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/j.annonc.2021.07.006","article-title":"Soft tissue and visceral sarcomas: Esmo-Euracan-Genturis Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Gronchi","year":"2021","journal-title":"Ann Oncol"},{"key":"B2","volume-title":"SEER cancer statistics review 1975-2017","year":"2020"},{"key":"B3","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ejca.2020.09.021","article-title":"Age-related differences of oncological outcomes in primary extremity soft tissue sarcoma: a multistate model including 6260 patients","volume":"141","author":"Acem","year":"2020","journal-title":"Eur J Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1248\/bpb.b21-01098","article-title":"Dose individualization of oral multi-kinase inhibitors for the implementation of therapeutic drug monitoring","volume":"45","author":"Noda","year":"2022","journal-title":"Biol Pharm Bull"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"van der Graaf","year":"2012","journal-title":"Lancet"},{"key":"B6","first-page":"1324","article-title":"Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy","volume":"9","author":"Sloan","year":"2008","journal-title":"Curr Opin Investig Drugs"},{"key":"B7","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.critrevonc.2010.02.012","article-title":"Pazopanib: clinical development of a potent anti-angiogenic drug","volume":"77","author":"Schutz","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.2217\/fon-2022-0348","article-title":"Meta-analysis of pazopanib and trabectedin effectiveness in previously treated metastatic synovial sarcoma (second-line setting and beyond)","volume":"18","author":"Carroll","year":"2022","journal-title":"Future Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"8243","DOI":"10.1007\/s00432-023-04766-3","article-title":"Real-world outcomes of pazopanib in metastatic soft tissue sarcoma: a retrospective Turkish oncology group (TOG) study","volume":"149","author":"Bilici","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"207","DOI":"10.4103\/ijc.IJC_105_18","article-title":"Pazopanib efficacy and toxicity in a metastatic sarcoma cohort: are Indian patients different?","volume":"56","author":"Sharma","year":"2019","journal-title":"Indian J Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3390\/medsci7030048","article-title":"Real-world experiences with pazopanib in patients with advanced soft tissue and bone sarcoma in northern California","volume":"7","author":"Seto","year":"2019","journal-title":"Med Sci (Basel)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"6755","DOI":"10.2147\/CMAR.S323499","article-title":"Real-world outcome and prognostic factors of pazopanib in advanced soft tissue sarcoma","volume":"13","author":"Alshamsan","year":"2021","journal-title":"Cancer Manag Res"},{"key":"B13","first-page":"205","article-title":"Treatment strategies for hereditary kidney cancer: current recommendations and updates","volume":"34","author":"Singh","year":"2022","journal-title":"Discov Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1200\/JCO.2008.21.3223","article-title":"Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043)","volume":"27","author":"Sleijfer","year":"2009","journal-title":"J Clin Oncol"},{"key":"B15","volume-title":"Hungary: country Health profile 2021, state of Health in the EU","year":"2021"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1610668","DOI":"10.3389\/pore.2022.1610668","article-title":"Comparison of cancer survival trends in Hungary in the periods 2001-2005 and 2011-2015 according to a population-based cancer Registry","volume":"28","author":"Kenessey","year":"2022","journal-title":"Pathol Oncol Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s11523-020-00731-z","article-title":"Real-world outcomes of pazopanib treatment in Korean patients with advanced soft tissue sarcoma: a multicenter retrospective cohort study","volume":"15","author":"Oh","year":"2020","journal-title":"Target Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1016\/j.ejca.2014.04.015","article-title":"Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies","volume":"50","author":"Widmer","year":"2014","journal-title":"Eur J Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1111\/bcp.14580","article-title":"Pharmacokinetically guided dosing has the potential to improve real-world outcomes of pazopanib","volume":"87","author":"Fukudo","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"494","DOI":"10.14744\/ejmi.2023.79254","article-title":"Pazopanib treatment in soft tissue sarcoma (single center experience)","author":"Metin","year":"2023","journal-title":"Eur J Med Invest"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e2036741","DOI":"10.1001\/jamanetworkopen.2020.36741","article-title":"Comparison of Solid tumor treatment response observed in clinical practice with response reported in clinical trials","volume":"4","author":"Feinberg","year":"2021","journal-title":"JAMA Netw Open"}],"container-title":["Pathology and Oncology Research"],"original-title":[],"link":[{"URL":"https:\/\/www.por-journal.com\/articles\/10.3389\/pore.2025.1611965\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T05:02:09Z","timestamp":1743483729000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.por-journal.com\/articles\/10.3389\/pore.2025.1611965\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":21,"alternative-id":["10.3389\/pore.2025.1611965"],"URL":"https:\/\/doi.org\/10.3389\/pore.2025.1611965","relation":{},"ISSN":["1532-2807"],"issn-type":[{"value":"1532-2807","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,1]]},"article-number":"1611965"}}